Inhibrx Biosciences Sees Leadership Changes with New Appointments

Leadership Changes at Inhibrx Biosciences

Inhibrx Biosciences, Inc., a biopharmaceutical player known for its clinical-stage developments, has undergone major leadership changes recently. On April 1, 2025, the company announced the departure of Dr. Brendan Eckelman, its co-founder and Chief Scientific Officer (CSO), and revealed the appointments of Dr. Carlos Bais as the new CSO and David Matly as the President of the company.

A New Chapter for Dr. Eckelman

Dr. Eckelman, who has been a pivotal figure in Inhibrx since its inception 15 years ago, is setting out to create a new venture—a private biotechnology firm. He expressed immense satisfaction regarding his time at Inhibrx, acknowledging the groundbreaking innovations achieved during his tenure. Inhibrx and the new enterprise have signed an exclusive licensing agreement concerning specific technologies no longer on Inhibrx's roadmap, which includes an upfront payment contingent on the funding of the new company, highlighting the ongoing relationship between Dr. Eckelman and his former firm.

Mark Lappe, the CEO of Inhibrx, recognized Dr. Eckelman’s contributions by stating, "Brendan has had a profound impact on Inhibrx, and we expect he will excel in his new endeavors as well." This collaborative spirit, even post-departure, underscores the culture of innovation entrenched within the company.

New Leaders Set to Drive Growth

With Dr. Eckelman’s exit, Dr. Bais has stepped up from his role as Executive Vice President of Translational Sciences to fill the prestigious CSO position. Dr. Bais’s extensive background includes pivotal roles at Genentech and Medimmune/Astrazeneca, showcasing a rich history of achievements in the biopharma space. His expertise, particularly in late-stage development, positions him as an ideal candidate to lead Inhibrx’s scientific endeavors into the future.

Simultaneously, David Matly has transitioned into the role of President, while retaining his responsibilities as Chief Commercial and Business Development Officer. Matly’s track record at Inhibrx includes being instrumental in the asset sale of INBRX-101 to Sanofi, which could yield up to $2.2 billion. In his new capacity, he will oversee clinical development, technical operations, and regulatory affairs, showcasing the company’s growth in managing complex operations efficiently.

A Bright Future Ahead

Lappe communicated optimism regarding these leadership transitions, stating, "We believe we are exceptionally well-positioned for continued success as Carlos steps into the role of CSO and David into the role of President." Both appointments signal a continuity of the company's commitment toward therapeutic innovation and the delivery of high-value treatments to patients while maximizing shareholder interests.

As Inhibrx moves forward, its clinical pipeline remains promising, with key data readouts expected in 2025 for therapeutic candidates like ozekibart (INBRX-109) and INBRX-106.

About Inhibrx Biosciences

Inhibrx is known for leveraging various protein engineering methodologies to design novel therapeutic candidates, which cater to specific complex disease mechanisms. Established in January 2024 as a subsidiary of Inhibrx, Inc., the company is on an ambitious path following its asset sale to Sanofi. Inhibrx aims to continue building a robust pipeline, bringing innovative solutions to the market within the biopharmaceutical realm.

As company dynamics evolve with the new appointments of Dr. Bais and Mr. Matly, stakeholders will be keenly observing how these leadership changes will impact Inhibrx's trajectory in the competitive biopharmaceutical industry.